Samsung Biologics Expands Rapid Micro Biosystems' Growth Direct Platform Deployment
Event summary
- Samsung Biologics placed a follow-on multi-system order for Rapid Micro Biosystems' Growth Direct platform on March 12, 2026.
- The order supports Samsung Biologics' expansion of microbial quality control automation across its manufacturing network.
- Robert Spignesi, President and CEO of Rapid Micro Biosystems, highlighted the partnership's focus on advanced automation and digitalization.
- The Growth Direct platform is designed to deliver faster results, greater accuracy, and stronger data integrity for microbial quality control.
The big picture
This follow-on order underscores the growing demand for automated microbial quality control in biopharmaceutical manufacturing. Samsung Biologics' continued investment in the Growth Direct platform highlights the strategic importance of automation in maintaining high productivity and quality in contract development and manufacturing operations. The deal also reflects broader industry trends toward digitalization and advanced automation in pharmaceutical production.
What we're watching
- Platform Scalability
- How Rapid Micro Biosystems will manage the pace of Growth Direct platform deployments across Samsung Biologics' global network.
- Market Positioning
- Whether this follow-on order signals a broader trend of CDMOs adopting automated microbial quality control solutions.
- Operational Integration
- The extent to which Growth Direct platform's seamless connectivity enhances Samsung Biologics' next-generation manufacturing operations.
Related topics